Corgi TER 2x Daily ETF
TERC
Chicago Board Options Exchange- -
USD
- -
- -
- -
- -
(- -)
Recent
price
- -
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Corgi TER 2x Daily ETF is a non-diversified, exchange-traded fund sponsored by Corgi Funds and managed by Corgi Strategies, LLC, designed to provide investors with leveraged, single-stock exposure to Teradyne, Inc. (NASDAQ: TER). The fund seeks daily investment results, before fees and expenses, equal to 200% of the daily performance of Teradyne common stock, rather than a two-times return over periods longer than one trading day. TERC primarily obtains its exposure through financial instruments, including total return swaps, futures and other derivatives, and generally invests at least 80% of net assets, plus borrowings for investment purposes, in instruments providing aggregate leveraged exposure approximating twice Teradyne’s daily performance; it also holds cash, cash equivalents and collateral, including U.S. government money-market instruments. The ETF targets investors seeking tactical exposure to Teradyne, a provider of automated test equipment, robotics and semiconductor-related automation technologies, and is subject to amplified daily volatility, compounding effects, financing costs and potential losses associated with leveraged investment strategies. TERC trades on Cboe BZX Exchange under the ticker symbol TERC and carries a 0.45% expense ratio. Corgi Funds, founded in 2025, is a U.S.-focused ETF sponsor offering thematic, buffer and leveraged ETF strategies designed to provide access to disruptive technology themes and targeted market exposures. A principal recent development is the launch and exchange listing of TERC in July 2026, expanding Corgi’s leveraged single-stock ETF lineup with two-times daily exposure to Teradyne.